Monte Rosa Therapeutics, Inc. Insider Trading Activity
Every SEC Form 4 insider transaction reported for Monte Rosa Therapeutics, Inc. (GLUE), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud · Insider-trading data from SEC EDGAR
Latest filing:
Compiled automatically from SEC EDGAR Form 4 filings and refreshed daily. Figures count purchases (code P) and sales (code S) only — not grants, option exercises, or gifts. How this page is built. Not investment advice.
Quick Answer
Are GLUE insiders buying or selling?
In the last 12 months, Monte Rosa Therapeutics, Inc. insiders reported 0 open-market purchases ($0) and 25 sales ($3.8M) — net selling of $3.8M. Since June 2021, Trabud has recorded 48 Form 4 filings for GLUE: 17 buys ($276.8M) and 31 sells ($16.1M).
Source: SEC EDGAR Form 4
Key Statistics (June 2021 – Oct 6, 2026)
Total Form 4 filings
48
SEC EDGAR
Insider filers
25
Insider buys (17)
$276.8M
Insider sells (31)
$16.1M
Insider sentiment
Net buyingNet insider flow of $260.7M in net buying since June 2021, and $3.8M in net selling over the last 12 months.
Recent GLUE insider transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Oct 6, 2026 | Matthew Bowen | Principal Accounting Officer | Sale | 13 | $10.56 | $137.28 | SEC ↗ |
| Jul 17, 2026 | Markus Warmuth | President & CEO | Sale | 9.5K | $23.18 | $220.2K | SEC ↗ |
| Jul 16, 2026 | Jennifer Champoux | Chief Operating Officer | Sale | 4.4K | $23.38 | $101.7K | SEC ↗ |
| Jul 7, 2026 | Sharon Townson | Chief Scientific Officer | Sale | 6.0K | $23.31 | $139.8K | SEC ↗ |
| Jul 1, 2026 | Filip Janku | Chief Medical Officer | Sale | 5.4K | $24.50 | $132.5K | SEC ↗ |
| Jun 30, 2026 | Filip Janku | Chief Medical Officer | Sale | 6.0K | $22.95 | $137.7K | SEC ↗ |
| Jun 30, 2026 | Anthony M. Manning | Director | Sale | 10.0K | $23.11 | $231.1K | SEC ↗ |
| Jun 25, 2026 | Filip Janku | Chief Medical Officer | Sale | 41.8K | $21.08 | $882.2K | SEC ↗ |
| Jun 25, 2026 | Jennifer Champoux | Chief Operating Officer | Sale | 2.2K | $20.00 | $43.5K | SEC ↗ |
| Jun 25, 2026 | Sharon Townson | Chief Scientific Officer | Sale | 3.0K | $20.00 | $60.0K | SEC ↗ |
| Jun 18, 2026 | Jennifer Champoux | Chief Operating Officer | Sale | 2.2K | $19.00 | $41.3K | SEC ↗ |
| Jun 18, 2026 | Sharon Townson | Chief Scientific Officer | Sale | 3.0K | $19.00 | $57.0K | SEC ↗ |
| Jun 2, 2026 | Markus Warmuth | President & CEO | Sale | 5.5K | $19.44 | $106.3K | SEC ↗ |
| Jun 1, 2026 | Sharon Townson | Chief Scientific Officer | Sale | 6.0K | $19.87 | $119.2K | SEC ↗ |
| May 28, 2026 | Jennifer Champoux | Chief Operating Officer | Sale | 2.2K | $20.00 | $43.5K | SEC ↗ |
| May 26, 2026 | Jennifer Champoux | Chief Operating Officer | Sale | 2.2K | $19.00 | $41.3K | SEC ↗ |
| May 22, 2026 | Anthony M. Manning | Director | Sale | 10.0K | $18.01 | $180.1K | SEC ↗ |
| May 5, 2026 | Markus Warmuth | President & CEO | Sale | 5.5K | $18.92 | $103.4K | SEC ↗ |
| Apr 15, 2026 | Markus Warmuth | President & CEO | Sale | 8.0K | $17.64 | $141.1K | SEC ↗ |
| Apr 10, 2026 | Philip Nickson | Chief Business & Legal Officer | Sale | 5.8K | $17.69 | $103.4K | SEC ↗ |
| Mar 5, 2026 | Edmund Dunn | Principal Accounting Officer | Sale | 139 | $17.96 | $2.5K | SEC ↗ |
| Mar 4, 2026 | Markus Warmuth | President & CEO | Sale | 5.5K | $17.92 | $98.0K | SEC ↗ |
| Mar 2, 2026 | Edmund Dunn | Principal Accounting Officer | Sale | 25.7K | $18.09 | $464.9K | SEC ↗ |
| Feb 24, 2026 | Filip Janku | Chief Medical Officer | Sale | 9.2K | $19.50 | $179.2K | SEC ↗ |
| Jan 9, 2026 | Markus Warmuth | President & CEO | Sale | 5.5K | $23.49 | $128.4K | SEC ↗ |
Showing the 25 most recent of 48 Form 4 filings for Monte Rosa Therapeutics, Inc..
Most active GLUE insiders
- Markus Warmuth6 filings
- Edmund Dunn5 filings
- Jennifer Champoux5 filings
- Filip Janku4 filings
- Sharon Townson4 filings
Ask anything about GLUE insider activity
Use Trabud's AI agent to query Monte Rosa Therapeutics, Inc.'s Form 4 history in plain English — "Show me GLUE CEO purchases this year" or compare it against any other ticker.
Open the AI agentGLUE insider trading FAQ
Are Monte Rosa Therapeutics, Inc. insiders buying or selling?
In the last 12 months, Monte Rosa Therapeutics, Inc. insiders reported 0 open-market purchases ($0) and 25 sales ($3.8M) — net selling of $3.8M. Since June 2021, Trabud has recorded 48 Form 4 filings for GLUE: 17 buys ($276.8M) and 31 sells ($16.1M). Over the full record that is net buying of $260.7M.
How many insiders trade GLUE stock?
25 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for Monte Rosa Therapeutics, Inc.. The most recent filing was accepted on Oct 6, 2026.
Where does Trabud get GLUE insider trading data?
All GLUE insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.